Market Place
Sourcing Support
Ocumension Shows Strong Resilience And Commercialization Growth
12 Aug 2024 //
PR NEWSWIRE
OcuMension Acquires Alcon Eye Drops Rights For 16.7% Equity Stake
12 Aug 2024 //
PR NEWSWIRE
China approves treatment for chronic non-infectious eye inflammation
23 Jun 2022 //
BIOSPECTRUMASIA
In a first, China approves eye implant based solely on RWD
22 Jun 2022 //
FIERCEPHARMA
Ocumension Therapeutics Announces 2021 Interim Results
20 Aug 2021 //
PRNEWSWIRE
Alimera Sciences Receives $20 Million From Ocumension Therapeutics
14 Apr 2021 //
GLOBENEWSWIRE
Ocumension Therapeutics invests $15.7 million in EyePoint Pharmaceuticals
04 Jan 2021 //
PHARMABIZ
Ocumension Therapeutics Strengthens Pipeline for Posterior Segment Eye Diseases
02 Nov 2020 //
PIPELINEREVIEW
Ocumension strengthens pipeline for posterior segment eye diseases in China
30 Oct 2020 //
BIOSPECTRUMASIA
Ocumension strengthens pipeline for posterior segment eye diseases in China
30 Oct 2020 //
BIOSPECTRUMASIA
Nicox Selects 0.1% NCX 470 Dose in Adaptive Stage of Mont Blanc Phase 3 Trial
23 Sep 2020 //
GLOBENEWSWIRE
EyePoint Receives $9.5 Million in Upfront Cash from Ocumension Therapeutics
20 Aug 2020 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.